The Hutchison China MediTech Ltd – (HCM) Downgraded by Zacks Investment Research to “Sell”

The Hutchison China MediTech Ltd – (HCM) Downgraded by Zacks Investment Research to “Sell”

According to Zacks, “Hutchison China MediTech Limited researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. The Company offers drugs for oncology and autoimmune diseases treatment. Hutchison China MediTech Limited is based in Hong Kong. “

Zacks Investment Research lowered shares of Hutchison China MediTech Ltd – (NASDAQ:HCM) from a hold rating to a sell rating in a research report released on Monday, May 15th.

Several other research firms also recently issued reports on HCM. Canaccord Genuity set a $20.00 price objective on Hutchison China MediTech Ltd – and gave the stock a buy rating in a report on Saturday, March 11th. Stifel Nicolaus reaffirmed a buy rating and set a $22.00 price objective (up previously from $20.00) on shares of Hutchison China MediTech Ltd – in a report on Tuesday, March 14th. Shares of Hutchison China MediTech Ltd – (NASDAQ:HCM) opened at 20.59 on Monday. The company’s 50-day moving average price is $19.65 and its 200 day moving average price is $16.17. Hutchison China MediTech Ltd – has a 1-year low of $10.61 and a 1-year high of $21.78. The stock has a market cap of $2.50 billion and a PE ratio of 210.10.

Hedge funds have recently added to or reduced their stakes in the stock. Baillie Gifford & Co. boosted its stake in Hutchison China MediTech Ltd – by 0.5% in the fourth quarter. Baillie Gifford & Co. now owns 153,703 shares of the company’s stock worth $2,086,000 after buying an additional 777 shares in the last quarter. Waverton Investment Management Ltd boosted its stake in Hutchison China MediTech Ltd – by 16.5% in the first quarter. Waverton Investment Management Ltd now owns 140,988 shares of the company’s stock worth $2,813,000 after buying an additional 20,000 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in Hutchison China MediTech Ltd – during the first quarter worth approximately $618,000. Wellington Management Group LLP boosted its stake in Hutchison China MediTech Ltd – by 7.4% in the first quarter. Wellington Management Group LLP now owns 510,826 shares of the company’s stock worth $10,190,000 after buying an additional 35,053 shares in the last quarter. Finally, Schroder Investment Management Group boosted its stake in Hutchison China MediTech Ltd – by 6.8% in the first quarter. Schroder Investment Management Group now owns 976,364 shares of the company’s stock worth $20,084,000 after buying an additional 62,045 shares in the last quarter. Institutional investors and hedge funds own 3.64% of the company’s stock. Hutchison China MediTech Ltd – Company Profile

Hutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:HCM”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”}); Get a free copy of the Zacks research report on Hutchison China MediTech Ltd – (HCM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com Receive News & Ratings for Hutchison China MediTech Ltd – Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Hutchison China MediTech Ltd – and related companies with our FREE daily email newsletter.

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Related posts

Leave a Comment